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doi:10.101Genetic Variation in Donor CTLA-4 Regulatory Region
is a Strong Predictor of Outcome after Allogeneic
Hematopoietic Cell Transplantation for Hematologic
Malignancies
Madan Jagasia,1 William B. Clark,2 Kristin D. Brown-Gentry,3
Dana C. Crawford,3 Kang-Hsien Fan,4 Heidi Chen,4 Adetola Kassim,1
John P. Greer,1 Brian G. Engelhardt,1 Bipin N. Savani1Relapse remains a major cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). Graft-
versus-tumor effect is primarily mediated by donor T cells. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is
a critical inhibitor of T cell proliferation. Single nucleotide polymorphisms (SNPs) in CTLA-4 may affect
immune responses. We hypothesized that CTLA-4 SNPs will be associated with disease control after
allo-HCT. One hundred sixty-four adult patients with the availability of pretransplantation recipient and do-
nor DNA samples were included in this analysis. Ten tagSNPs of the CTLA-4 gene were identified. Donor
CTLA-4 SNP rs4553808 was associated with decreased relapse-free survival (RFS) (P 5 .019) and
overall survival (OS) (P 5 .033). In multivariable analysis of an additive genetic model, genotype of CTLA-4
SNP rs4553808 was an independent risk factor for inferior RFS (hazard ratio [HR] 5 1.73, 95% confidence
interval [CI] 1.10-2.71, P5.017) and OS (HR5 1.84, 95% CI 1.13-3.0, P5.015). CTLA-4 SNPs can be used to
identify high-risk patient subsets that may benefit from preemptive immunomodulation to decrease relapse
rates and improve survival.
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Relapse of the underlying malignancy after
allogeneic hematopoietic stem cell transplantation
(allo-HSCT) remains a major cause of transplant
failure. Although several clinical variables, including
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6/j.bbmt.2011.12.518versus-host disease (GVHD) prophylaxis, and condi-
tioning regimen, contribute to the risk of relapse,
predictors of graft-versus-tumor (GVT) effect remain
largely elusive. T cell homeostasis is critical in
determining the potency of the GVT effect [1-3].
Cytotoxic T lymphocyte antigen-4 (CTLA-4 or
CD152) is a member of the immunoglobulin super
family and is a negative regulator of T cell activation.
After the initial recognition of antigen by the T cell
receptor complex, the primary positive costimulatory
signal is the binding of CD28 on T cells to CD80/
CD86 on antigen-presenting cells. CTLA-4 is
expressed on T cells after activation and exerts its
negative regulatory effects by competing with CD28
for CD80/CD86 and blocking downstream activation
pathways. CTLA-4 is highly conserved among
mammals, indicating the importance of inhibiting
proliferation and in inducing peripheral tolerance in
T cells [4].
Single nucleotide polymorphisms (SNPs) in
CTLA-4may lead to differential expression, transcrip-
tion, or translation and may affect the balance of T cell
homeostasis [4]. SNPs of CTLA-4 have been shown to
be important risk factors associated with autoimmune1069
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SNPs (G allele of rs4553808, T allele of rs11571317,
and A allele of rs231775) were associated with
positive response to ipilimumab (anti-CTLA-4-
antibody) therapy [9].
Patients with chronic (cGVHD) have a lower risk
of relapse, and cGVHD is often used as a surrogate
marker of GVT effect. We hypothesized that genetic
variation in donor CTLA-4 would impact relapse-
free (RFS) and overall survival (OS) of recipients after
allo-HSCT independent of cGVHD status.METHODS
Adult patients undergoing matched related or
unrelated allo-HSCT at Vanderbilt University Medi-
cal Center from January 1999 to September 2008
with availability of pretransplantation germline recip-
ient and donor DNA samples, and surviving until
day 100 post-allo-HSCT were included in this study.
Younger age (\18 years), mismatched, and cord blood
transplant recipients were excluded. The final cohort
consisted of 164 recipient-donor pairs. Chronic
GVHD classification and severity was determined
per NIH criteria (Table 1) [10]. All patients were
transplanted on institutional review board or standard
of care approved protocols.
SNP Selection and Genotyping
There are 83 SNPs of CTLA-4. A total of 10
tagSNPS were targeted for genotyping. TagSNPs
were identified using linkage disequilibrium selected
via the Genome Variation Server (Build 5.09) on the
SeattleSNPs Website (http://gvs.gs.washington.edu/
GVS/) using a combination of Seattle SNPs and Hap-
Map with the following parameters: (1) minor allele
frequency of.10%; (2) r2 threshold..80; and (3) ref-
erence sequence encompassing 2 kb 50 and 30 flanking
region. Whole genome amplification was performed
using the REPLI-g UltraFast Mini-Kit (QIAGEN,
Chatsworth, CA). Whole genome amplification was
verified by RNASE-P analysis on the Taqman 7200.
Genotyping of amplified DNA was performed with
a custom GoldenGate (Illumina, San Diego, CA)
combined with VeraCode technology on the Bead-
Xpress reader system according to the manufacturer’s
protocol (Illumina).
Statistical Analysis
The primary endpoint for the study was to test for
associations between CTLA-4 SNPs and RFS and OS.
Classic and overlap were combined as 1 category as
both these groups have features of cGVHD. Descrip-
tive statistics, including median and range for continu-
ous variables as well as percentages and frequencies
for categorical variables, were calculated. To test fordifferences between the 2 groups, a chi-square test
was used for the categoric variables and a Wilcoxon
rank sum test for the continuous variables. All SNPs an-
alyzed passed quality control (test of Hardy-Weinberg
equilibrium P . .001, minor allele frequency .0.10,
SNP call rate .0.95, and pair-wise r2 value \.80),
and linkage disequilibrium was calculated for donors
and recipients. All single SNP tests of association
were performed using PLINK (http://pngu.mgh.
harvard.edu/purcell/plink/) and included all
European-American individuals: 153 donors and 156
recipients. The log-rank test was used to compare
time to event analyses. For univariate analysis, a test
of association between CTLA4 SNPs and survival was
done using an unadjusted additive genetic model. Be-
cause of the exploratory nature of the analysis, no ad-
justment on P values was made. SNPs retaining
significance in univariate analyses were included in
Cox proportional hazards multivariable model. All sta-
tistical analyses were performed using PLINK and R
2.10.1 (http://www.R-project.org).RESULTS
Patients
Patient characteristics are summarized in Table 1.
Median follow-up from the day of post-allo-HCT was
1.45 years (range: 0.30 to 9.0). GVHD after day 100
occurred in 124 (76%) patients (recurrent/persistent/
delayed acute GVHD [aGVHD] [N 5 23], overlap
cGVHD [N 5 29], and classic cGVHD [N 5 72]).
The 2-year OS and 2-year RFS of the entire cohort
was 63% (95% confidence interval [CI], 55-72) and
60% (95% CI, 53-69), respectively.Univariate Analysis
Because of shared clinical phenotype and similar
survival characteristics, overlap and classic cGVHD
were combined into a single outcome variable. There
were no significant differences in clinical characteris-
tics between patients with or without classic plus over-
lap cGVHD (Table 1). CTLA-4 SNPs (both recipient
and donor) were not associated with GVHD pheno-
type beyond day 100 post-allo-HCT. Patients with
low, intermediate, and high-risk disease status had
a 2-year RFS (60%, 63%, 44%, P 5 .108) and 2-year
OS (63%, 65%, 46%, P 5 .156), respectively. Other
variables, including age, stem cell source, regimen
intensity, and diagnosis, were not associated with
either RFS or OS (data not shown). Recipient SNPs
of CTLA-4 were not significantly associated with
RFS or OS (data not shown). In single SNP analysis,
1 donor SNP, rs4553808 (A/G -1661) (Table 2), was
significantly associated with RFS (Figure 1A) and OS
(Figure 1B). Of the 153 donors, 103 (67%), 43
Table 1. Patient Characteristics (N 5 164)
Variable
N (%) GVHD Subtype
Total cohort
(N 5 164)
Classic plus overlap cGVHD
N (%) (N 5 101)
aGVHD subtypes plus no GVHD
N (%) (N 5 63)
Pretransplantation characteristics
Age, median in years (range) 47 (18-69) 49 (21-67) 46 (18-69)
Gender
Male (R) 80 (49) 49 (49) 31 (49)
Female (R) 84 (51) 52 (51) 32 (51)
Female D to male R 31 (19) 21 (21) 10 (19)
Race
Caucasian (R/D) 156 (95)/153 (93) 94 (93)/92 (91) 62 (98)/61 (97)
Diagnoses
Acute leukemia 86 (52) 49 (49) 37 (59)
Chronic Leukemia 19 (12) 11 (11) 8 (13)
Lymphoma 54 (33) 38 (37) 16 (25)
Other 5 (3) 3 (3) 2 (3)
Disease risk*
Low 65 (40) 38 (38) 27 (43)
Intermediate 30 (18) 21 (20) 9 (14)
High 40 (24) 25 (25) 15 (24)
Missing 29 (18) 17 (17) 12 (19)
Stem cell source
Marrow 44 (27) 23 (22) 21 (33)
Peripheral blood stem cells 120 (73) 78 (78) 42 (67)
Regimen intensity
Myeloablative 111 (68) 69 (68) 42 (67)
Other 53 (32) 32 (32) 21 (33)
Donor type
Related 109 (67) 69 (68) 40 (63)
Unrelated 55 (33) 32 (32) 23 (37)
HLA match
HLA identical sibling 108 (66) 68 (67) 40 (63)
HLA matched unrelated 55 (33) 32 (32) 23 (37)
Other 1 (1) 1 (1) 0
GVHD prophylaxis
CSA/MTX 112 (68) 72 (71) 40 (63)
CSA/MMF 50 (31) 28 (28) 22 (36)
Other 2 (1) 1 (1) 1 (1)
TBI
Yes 79 (48) 52 (51) 27 (43)
No 85(52) 49 (49) 36 (57)
CMV
R/D (+/+) 63 (38) 35 (34) 28 (44)
R/D (+/2) 19 (12) 12 (12) 7 (11)
R/D (2/+) 47 (29) 29 (29) 18 (29)
R/D (2/2) 35 (21) 25 (25) 10 (16)
Posttransplantation characteristics
aGVHD†
Grade 0-2 vs. 3-4 129 (78) vs. 32 (20) 78 (77) vs. 21 (21) 51 (81) vs. 11 (17)
Grade 0-1 vs. 2-4 39 (24) vs. 122 (74) 39 (24) vs. 75 (74) 15 (24) vs. 47 (75)
PLT (X109/L) at day 100, median (range) 110 (10-356) 105 (17-244) 112 (10-356)
Total bilirubin (mg/dL) at day 100, median (range) 0.8 (0-3.6) 0.8 (0-2.4) 0.9 (0.2-3.6)
GVHD indicates graft-versus-host disease; cGVHD, chronic GVHD; aGVHD, acute GVHD; R, recipient; D, donor; HLA, human leukocyte antigen; CSA,
cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; TBI, total body irradiation; CMV, cytomegalovirus; PLT, platelet; OS, overall survival;
RFS, relapse-free survival; CI, confidence interval.
*Disease risk based on Committee of International Bone Marrow Transplant Registry (CIBMTR) risk criteria.
†aGVHD: 3 cases missing.
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rs4553808, respectively. All patients in the GG
genotype group relapsed, compared with 39 (38%)
and 19 (43%) in the AA and AG genotype groups
(Figure 1C).
Multivariable Analysis
Multivariable analyses were adjusted for variables
that have been associated with cGVHD and risk ofrelapse post-allo-HCT. Thus, the Cox proportional
hazards model was adjusted for stem cell source,
disease risk, and type of GVHD beyond day 100
post-allo-HCT (classic 1 overlap versus no 1
aGVHD subtypes). A/G or G/G genotype of
CTLA-4 SNP rs4553808 was an independent risk
factor for both RFS (hazard ratio [HR] 5 1.73, 95%
CI, 1.10-2.71, P 5 .017) and OS (HR 5 1.84, 95%
CI, 1.13-3.0, P 5 .015) (Table 3).
Table 2. Univariate Analysis of Donor CTLA-4 Polymorphisms by RFS and OS
SNP Gene Allele Minor MAF (%)
RFS OS
HR 95% CI P P* P# HR 95%CI P P* P#
rs11571315 Intron T/C T 41 1.06 0.7-1.60 .80 1.00 .89 1.09 0.71-1.70 .69 1.00 .77
rs4553808 Intron G/A G 12 1.62 1.04-2.51 .04 .20 .40 1.78 1.12-2.81 .02 .20 .20
rs11571316 Intron A/G A 46 1.20 0.83-1.72 .33 1.00 .70 1.23 0.84-1.81 .29 1.00 .72
rs16840252 Intron T/C T 14 0.67 0.42-1.06 .10 1.00 .50 0.62 0.38-0.99 .06 .60 .30
rs231775 Intron G/A G 40 0.95 0.64-1.40 .80 1.00 .89 0.89 0.59-1.36 .59 1.00 .76
rs231777 Intron T/C T 13 0.79 0.49-1.28 .35 1.00 .70 0.73 0.44-1.22 .24 1.00 .72
rs231779 Intron T/C T 40 1.05 0.71-1.58 .80 1.00 .89 1.12 0.73-1.71 .61 1.00 .76
rs3087243 Intron A/G A 46 1.17 0.82-1.67 .39 1.00 .70 1.17 0.80-1.72 .41 1.00 .76
rs1019701 Intron C/A C 15 1.00 0.67-1.57 .99 1.00 .99 0.97 0.59-1.60 .92 1.00 .92
rs231725 Intron A/G A 33 0.85 0.57-1.27 .42 1.00 .70 0.87 0.57-1.33 .52 1.00 .76
MAF indicates minor allele frequency; HR, hazard ratio; CI, confidence interval; P, P value; P*, P value obtained after Bonferroni correction; P#, P value
obtained from false discovery rate (FDR).
Bold font indicates SNP with statistically significant impact on RFS and OS.
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This study shows that genetic variation in donor
CTLA-4 is associated with RFS and OS after allo-
HCT. Although the association of CTLA4 SNP and
outcome after allo-HCT has been previously reported
[11-15], our study controls for the GVHD phenotype
beyond day 100 as defined by theNational Institutes of
Health Consensus Criteria and identifies a donor
CTLA4 SNP rs4553808 (A/G or G/G) genotype as
an independent pretransplantation predictor of both
RFS and OS.
The human CTLA-4 gene is located on 2q33, in
a susceptibility region for autoimmune disease. The
CTLA-4 gene is translated into two proteic isoforms:
a full-length protein (flCTLA-4) and a soluble coun-
terpart (sCTLA-4), which lacks exon 3 (responsible
for coding the transmembrane domain) because of
alternative splicing. flCTLA-4 down-regulates T cell
responses by inducing cell cycle arrest and blocking
cytokine production [16,17]. CTLA-4 is expressed
on T cells after activation and exerts its negative regu-
latory effects by sequestering CD28. This prevents the
binding of CD28 to CD80/CD86 and prevents costi-
mulatory signal, thus blocking downstream activation
pathways. The exact mechanism by which CTLA-4
SNP modulates CTLA-4 function is not known. GG
genotype ofCTLA-4 SNPCT60 (rs3087243) is associ-
ated with decreased production of sCTLA-4 [11]. In
the absence of sCTLA-4 competing with flCTLA-4
for the CD28 ligand, T cells are more likely to be
inactivated and less capable of detecting tumor anti-
gens, thus allowing minimal tumor to escape from
the suboptimal GVT effect. It is not known whether
a similar mechanism operates for rs4533808.
rs4553808 is in the upstream promoter region of
CTLA-4. Although the rs4553808 is less well charac-
terized than other SNPs in the CTLA-4 gene [4], it
has been associated with increased risk in multiple
sclerosis [18], type 1 diabetes mellitus [5,19] systemic
sclerosis [20], oral squamous cell carcinoma [7], andlymph node involvement in breast cancer [21], thus
suggesting a relationship between this SNP and
immune regulation/immune activation/autoimmu-
nity, which could translate into GVT response as
seen with this study.
Perez-Garcia et al. [11] have reported that the G
genotype of CT60 (rs3087243) confers an inferior
OS and RFS, but did not report on cGVHD. Vannuc-
chi et al. [12] identified the impact of 149 (rs231775)
and CT60 (rs308723) on aGVHD and cGVHD, but
did not report on OS and RFS. In an Italian cohort,
Azarian et al. [13] did not see any influence of 149
(rs231775) or CT60 (rs3087243) on OS, RFS, or
aGVHD, but reported a worse outcome on cGVHD
with a G genotype of CT60. Similar findings were
seen in a Tunisian cohort [14]. In a recent study of
T-depleted allogeneic transplant, the AA genotype of
CT60 (rs308723) was associated with an inferior OS
and RFS [22].
Treatment for relapse after allo-SCT is challeng-
ing because of the poor tolerance to standard chemo-
therapy regimens and lower efficacy of available
therapeutic options including second transplantation
[3,23]. Manipulating T cell homeostasis to optimize
GVT effect without increasing GVHD needs further
refinement to optimize outcomes after allo-HCT.
Donor CTLA-4 genotyping may identify a subset of
patients with a high risk of relapse that may benefit
from preemptive donor lymphocyte infusion or
customizing peritransplantation GVHD prophylaxis.
Antithymocyte globulin is often a part of GVHD
prophylaxis in unrelated donor allo-HCT. The
optimal dose of antithymocyte globulin remains
controversial [24-29]. Higher doses are associated
with increased risk of relapse and infections, whereas
low doses may not provide adequate GVHD
prophylaxis. It is possible that CTLA-4 SNPs
modulate the effect of antithymocyte globulin, and
patients with the rs4553808 A/G or G/G genotype
would be at a higher risk of relapse or infectious
complications after allo-HCT. This hypothesis needs
Figure 1. (A) Relapse-free survival; (B) overall survival; and (C) cumulative incidence of relapse with death from nonrelapse as a competing risk: strat-
ified by donor CTLA4 SNP rs4553808 genotype.
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patients with acute myeloid leukemia through collabo-
ration with the Center of International Blood and
Marrow Transplant Research.Table 3. Multivariable Analysis: RFS and OS
Variable
RFS OS
HR (95% CI) P HR (95% CI) P
rs4553808* (ref AA) 1.73 (1.10, 2.71) .016 1.84 (1.13, 3.0) .014
GVHD type (ref NIH
chronic/overlap)
2.73 (1.64, 4.56) <.001 2.31 (1.33, 4.01) .002
Stem cell source (ref BM) 1.19 (0.65, 2.19) .57 1.35 (0.69, 2.63) .377
Disease risk (ref low/
intermediate)
1.67 (0.93, 2.98) .09 1.98 (1.07, 3.68) .03
Ref indicates reference category; GVHD, graft-versus-host disease; BM,
bone marrow.
*Additive genetic model for each G allele.Ipilimumab, a CTLA4 antibody, has been studied
inmelanoma, and is the prototypic example of immune
modulation for the treatment of solid tumor. Ipilimu-
mab sequesters CTLA-4 and allows for interaction of
CD28 with CD80/CD86, which further augments
T cell activation by providing a costimulatory signal.
Recently, Hodi et al. [30] have shown that ipilimumab
improves OS in patients with melanoma. In patients
with melanoma, the G allele of rs4553808 in
CTLA-4 was associated with improved response to
ipilimumab [9]. Ipilimumab leads to immunemediated
diarrhea and colitis, a syndrome that closely mimics
gastrointestinal GVHD [31]. In a phase I clinical trial
of ipilimumab for relapse after allo-HCT, complete
remission was achieved in 2 patients with Hodgkin’s
lymphoma and partial remission in 1 patient with re-
fractory mantle cell lymphoma, suggesting that target-
ing CTLA-4 is feasible [32].
1074 Biol Blood Marrow Transplant 18:1069-1075, 2012M. Jagasia et al.Although our data have shown that the CTLA-4
SNPrs4553808genotypewas an independentpredictor
ofOS andRFS, a larger study in a homogenous patients
populations is needed to validate our findings. If
validated, this would allow pretransplantation donor
CTLA-4 genotyping as a risk-stratification tool to pre-
dict relapse risk. Patients at high risk of relapse could
specifically be targeted for immunodulation in the peri-
transplantation period, early posttransplantation pre-
emptive disease-specific therapy, or donor lymphocyte
infusions to optimize outcomes after transplantation.ACKNOWLEDGMENTS
The authors acknowledge Cara Sutcliffe, MS, and
Holli Dilks, PhD, DNA Resource Center, Center for
Human Genetics Research; Cindy Vnencak-Jones,
PhD, Molecular Diagnostics; Carey Clifton, ACNP,
Catherine Lucid, ACNP, and Leigh Ann Vaughan,
ACNP, Long-Term Transplant Clinic. The Vander-
bilt University for Human Genetics Research,
Computational Genetics Core, provided computa-
tional and analytical support for this work.
Financial disclosure: The authors have nothing to
disclose.AUTHORSHIP STATEMENT
Contribution: W.B.C. and M.H.J. designed the
research, analyzed data, and wrote the manuscript.
W.B.C., and J.S. performed experiments. K.D.G.B.
and D.C.C advised SNP assay design and analyzed
SNP data with PLINK. H.C., and K.H.F. analyzed
data and performed statistical analysis. B.N.S helped
with manuscript writing and provided critical input.
B.E., A.K., and J.P.G. provided critical review for the
manuscript.REFERENCES
1. Barrett AJ. Understanding and harnessing the graft-versus-
leukaemia effect. Br J Haematol. 2008;142:877-888.
2. vandenBrinkMR,MooreE,Ferrara JL,Burakoff SJ.Graft-versus-
host-disease-associated thymic damage results in the appearance
of T cell clones with anti-host reactivity. Transplantation. 2000;
69:446-449.
3. Miller JS, Warren EH, van den Brink MR, et al. NCI First
International Workshop on the biology, prevention, and
treatment of relapse after allogeneic hematopoietic stem cell
transplantation: report from the committee on the biology
underlying recurrence of malignant disease following allogeneic
HSCT: graft-versus-tumor/leukemia reaction. Biol Blood
Marrow Transplant. 2010;16:565-586.
4. TeftWA, KirchhofMG,Madrenas J. Amolecular perspective of
CTLA-4 function. Annu Rev Immunol. 2006;24:65-97.
5. Baniasadi V, Narain N, Goswami R, Das SN. Promoter region
2318C/T and21661 A/GCTLA-4 single nucleotide polymor-
phisms and type 1 diabetes in North Indians. Tissue Antigens.
2006;67:383-389.6. Brunner-Weinzierl MC, Hoff H, Burmester GR. Multiple
functions for CD28 and cytotoxic T lymphocyte antigen-4
during different phases of T cell responses: implications for
arthritis and autoimmune diseases. Arthritis Res Ther. 2004;6:
45-54.
7. Kammerer PW, Toyoshima T, Schoder F, et al. Association of
T-cell regulatory gene polymorphisms with oral squamous cell
carcinoma. Oral Oncol. 2010;46:543-548.
8. Sun T, Zhou Y, Yang M, et al. Functional genetic variations in
cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple
types of cancer. Cancer Res. 2008;68:7025-7034.
9. Breunis WB, Tarazona-Santos E, Chen R, et al. Influence of
cytotoxic T lymphocyte-associated antigen 4 (CTLA4) com-
mon polymorphisms on outcome in treatment of melanoma
patients with CTLA-4 blockade. J Immunother. 2008;31:
586-590.
10. Filipovich AH,Weisdorf D, Pavletic S, et al. National Institutes
of Health consensus development project on criteria for clinical
trials in chronic graft-versus-host disease: I. Diagnosis and
staging working group report. Biol Blood Marrow Transplant.
2005;11:945-956.
11. Perez-Garcia A, De la Camara R, Roman-Gomez J, et al.
CTLA-4 polymorphisms and clinical outcome after allogeneic
stem cell transplantation from HLA-identical sibling donors.
Blood. 2007;110:461-467.
12. Vannucchi AM, Guidi S, Guglielmelli P, et al. Significance of
CTLA-4 and CD14 genetic polymorphisms in clinical outcome
after allogeneic stem cell transplantation. Bone Marrow Trans-
plant. 2007;40:1001-1002.
13. Azarian M, Busson M, Lepage V, et al. Donor CTLA-4149 A/
G*GG genotype is associated with chronic GVHD after HLA-
identical haematopoietic stem-cell transplantations. Blood. 2007;
110:4623-4624.
14. Sellami MH, Bani M, Torjemane L, et al. Effect of donor
CTLA-4 alleles and haplotypes on graft-versus-host disease
occurrence in Tunisian patients receiving a human leukocyte
antigen-identical sibling hematopoietic stem cell transplant.
Hum Immunol. 2011;72:139-143.
15. Wu J, Tang JL, Wu SJ, Lio HY, Yang YC. Functional
polymorphism of CTLA-4 and ICOS genes in allogeneic
hematopoietic stem cell transplantation. Clin Chim Acta. 2009;
403:229-233.
16. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:
305-334.
17. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2
accumulation and cell cycle progression upon activation of
resting T cells. J Exp Med. 1996;183:2533-2540.
18. Yousefipour G, Erfani N, Momtahan M, Moghaddasi H,
Ghaderi A. CTLA4 exon 1 and promoter polymorphisms in
patients with multiple sclerosis. Acta Neurol Scand. 2009;120:
424-429.
19. Bouqbis L, Izaabel H, Akhayat O, et al. Association of the
CTLA4 promoter region (21661G allele) with type 1 diabetes
in the South Moroccan population. Genes Immun. 2003;4:
132-137.
20. Almasi S, Erfani N, Mojtahedi Z, Rajaee A, Ghaderi A.
Association of CTLA-4 gene promoter polymorphisms with
systemic sclerosis in Iranian population. Genes Immun. 2006;7:
401-406.
21. Erfani N, Razmkhah M, Talei AR, et al. Cytotoxic T lympho-
cyte antigen-4 promoter variants in breast cancer. Cancer Genet
Cytogenet. 2006;165:114-120.
22. Bosch-Vizcaya A, Perez-Garcia A, Brunet S, et al. Donor
CTLA-4 genotype influences clinical outcome after T cell-
depleted allogeneic hematopoietic stem cell transplantation
from HLA-identical sibling donors. Biol Blood Marrow
Transplant. 2011 Jun 12 [Epub ahead of print].
23. Clark WB, Strickland SA, Barrett AJ, Savani BN. Extramedul-
lary relapses after allogeneic stem cell transplantation for acute
myeloid leukemia andmyelodysplastic syndrome.Haematologica.
2010;95:860-863.
Biol Blood Marrow Transplant 18:1069-1075, 2012 1075CTLA-4 Polymorphism and Survival after SCT24. BacigalupoA,LamparelliT, Bruzzi P, et al. Antithymocyte glob-
ulin for graft-versus-host disease prophylaxis in transplants from
unrelated donors: 2 randomized studies from Gruppo Italiano
Trapianti Midollo Osseo (GITMO). Blood. 2001;98:2942-2947.
25. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin
prevents chronic graft-versus-host disease, chronic lungdysfunc-
tion, and late transplant-related mortality: long-term follow-up
of a randomized trial in patients undergoing unrelated donor
transplantation. Biol Blood Marrow Transplant. 2006;12:560-565.
26. Finke J, Schmoor C, LangH, Potthoff K, Bertz H.Matched and
mismatched allogeneic stem-cell transplantation from unrelated
donors using combined graft-versus-host disease prophylaxis
including rabbit anti-T lymphocyte globulin. J Clin Oncol.
2003;21:506-513.
27. Schleuning M, Gunther W, Tischer J, Ledderose G, Kolb HJ.
Dose-dependent effects of in vivo antithymocyte globulin
during conditioning for allogeneic bone marrow transplantation
from unrelated donors in patients with chronic phase CML.
Bone Marrow Transplant. 2003;32:243-250.28. Toor A, Rodriguez T, Bauml M, et al. Feasibility of condition-
ing with thymoglobulin and reduced intensity TBI to reduce
acute GVHD in recipients of allogeneic SCT. Bone Marrow
Transplant. 2008;42:723-731.
29. Zander AR, Kroger N, Schleuning M, et al. ATG as part of the
conditioning regimen reduces transplant-related mortality
(TRM) and improves overall survival after unrelated stem cell
transplantation in patients with chronic myelogenous leukemia
(CML). Bone Marrow Transplant. 2003;32:355-361.
30. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival
with ipilimumab in patients with metastatic melanoma. N Engl
J Med. 2010;363:711-723.
31. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic
T-lymphocyte antigen-4 by ipilimumab results in dysregulation
of gastrointestinal immunity in patients with advanced mela-
noma. Cancer Immun. 2010;10:11.
32. Bashey A,Medina B, CorringhamS, et al. CTLA4 blockadewith
ipilimumab to treat relapse of malignancy after allogeneic
hematopoietic cell transplantation. Blood. 2009;113:1581-1588.
